Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Pharmacology Study of NS-229 in Healthy Male Subjects (Drug-Drug Interaction with Prednisolone)
jRCT2051210094Phase 1Completed
- Sponsor
- Nippon Shinyaku
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NS-229 in Inflammatory Disorders, sponsored by Nippon Shinyaku. Primary endpoints: PK parameters of prednisolone (AUC0-t) and PK parameters of prednisolone (Cmax). Started Oct 2021; status: completed.
02
Drugs
NS-229
03
Conditions
Inflammatory Disorders
Beyond the preview
Go deeper on jRCT2051210094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210094.